
Therakos INSTITUTE™
ECP Immunomodulation

Shaping the future with you for more than 35 years

AGENDA

3 December 2026



International Expert Forum: Advancing Care in Pediatric GvHD – The Evolving Role of ECP

Hôpital Robert Debré, Paris, France

This information is intended for healthcare professionals in France

Agenda

Time: 08:30 – 12:50

Moderator	**Prof JH Dalle**, Robert Debré Hospital
08:30 – 09:00	**Welcome & coffee**
09:00 – 09:10	**Introduction and open remarks** **Prof JH Dalle**, Robert Debré Hospital
09:10 – 09:40	**Pediatric GvHD – The current landscape and unmet needs** **Prof JH Dalle**, Robert Debré Hospital
09:40 – 10:10	**Combination and sequential strategies in pediatric GvHD: the role of ECP** **Prof Cristina De Heredia**, Vall d'Hebron University Hospital
10:10 – 10:40	**Early use of ECP in the treatment of GvHD: Insights from Newcastle** **Prof Andrew Gennery,** University of Newcastle
10:40 – 11:10	**Break**
11:10 – 11:40	**Practical Realities – Implementing ECP in children** **Susana Roncon**, Portuguese Institute of Oncology, Lisbon
11:40 – 12:00	**Interactive clinical cases – Decision-making in pediatric GvHD** **Speaker TBC**
12:00 – 12:20	**Interactive clinical cases – Decision-making in pediatric GvHD** **Speaker TBC**
12:20 – 12:50	**Panel discussion – perspectives and challenges** **Moderator and all expert panel**

To confirm your attendance please email Lindsay.John@therakos.com

ECP: Extracorporeal Photopheresis, GvHD: Graft vs Host Disease

All speakers are subject to contract.

This is a commercial programme run by Therakos (UK) Ltd

Privacy policy

Follow the Therakos Institute

The THERAKOS™ CELLEX™ Photopheresis System is indicated: -in patients over 18 years of age for photopheresis in the following cases: Cutaneous T-cell lymphoma (CTCL), Solid organ transplant rejection (SOT) (heart, lung); in patients over 3 years of age for the management of the following: Acute and chronic graft-versus-host disease (aGvHD, cGvHD). Please see the THERAKOS™ CELLEX™ Photopheresis System operator's Manual for indications, contraindications, warnings, precautions, adverse reactions, and other important information. Class IIb medical device. Notified body: CE2797. Legal manufacturer: Mallinckrodt Pharmaceuticals Ireland Limited, College Business & Technology Park, Cruiserath Road, Blanchardstown, Dublin 15, Ireland.

Therakos, the circle mark and the Therakos logo are registered trademarks of Therakos Corporation. Other marks are either registered trademarks of Therakos Corporation or the respective owners. © 2026 Therakos. TKS-26-00228 05/2026.

Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating "unsubscribe" in the email body. Our privacy policy provides additional information.